Let’s see how things are shaping up for the first quarter of 2015.
Factors at Play This Quarter
Isis Pharma’s antisense drug delivery platform has resulted in partnerships with leading health care companies including Biogen BIIB and GlaxoSmithKline GSK among others and provides the company with a steady stream of funds in the form of upfront, milestone and other payments.
Isis Pharma’s net revenues, which shot up 100.9% to $84.9 million in the fourth quarter of 2014, are expected to rise in the first quarter of 2015 as well. During the first quarter, Isis Pharma received several milestone payments from partners Glaxo and Biogen which should boost revenues.
On the first quarter call, the focus will remain on Isis Pharma’s pipeline. The company expects several pipeline related news with multiple data readouts from several studies including ISIS-TTRRx (transthyretin amyloidosis – phase III with Glaxo), ISIS-SMNRx (spinal muscular atrophy in infants and children – phase III with Biogen) and ISIS-APOCIIIRx (familial chylomicronemia syndrome and partial lipodystrophy – phase III) among others.